A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma

A Phase 2 dose-finding study evaluated isatuximab, an anti-CD38 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM; NCT01084252). Patients with ≥3 prior lines or refractory to both immunomodulatory drugs and proteasome inhibitors (dual refractory) were randomized to isatuximab 3 mg/k...

Descripción completa

Detalles Bibliográficos
Autores principales: Mikhael, Joseph, Richter, Joshua, Vij, Ravi, Cole, Craig, Zonder, Jeffrey, Kaufman, Jonathan L., Bensinger, William, Dimopoulos, Meletios, Lendvai, Nikoletta, Hari, Parameswaran, Ocio, Enrique M., Gasparetto, Cristina, Kumar, Shaji, Oprea, Corina, Chiron, Marielle, Brillac, Claire, Charpentier, Eric, San-Miguel, Jesús, Martin, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685976/
https://www.ncbi.nlm.nih.gov/pubmed/32409691
http://dx.doi.org/10.1038/s41375-020-0857-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685976/
https://www.ncbi.nlm.nih.gov/pubmed/32409691
http://dx.doi.org/10.1038/s41375-020-0857-2

Ejemplares similares